Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments

• On 7 Apr 2026 Red Light Holland announced that its subsidiary Filament Health signed three new license agreements with leading research institutions in Australia (University of Melbourne), the United Kingdom (Imperial College London) and Canada (University of Calgary).
• The licences cover clinical studies of PEX010, a pharmaceutical‑grade botanical psilocybin, across functional neurological disorder, gambling disorder and PTSD.
• Two additional research shipments of PEX010 were completed to Canadian sites for safety/efficacy pilots and a Phase II trial in treatment‑resistant depression.
• The announcements come as Red Light moves toward finalising its definitive arrangement to acquire Filament Health, which would bring 76 patents, GMP manufacturing capacity and FDA/Health Canada‑authorized clinical programs into the combined entity.

Aspect	Assessment
Novelty	First time these specific university licences are disclosed; they were not anticipated in prior updates.
Scope	Adds three geographically diverse, high‑profile research partners and expands the clinical pipeline for PEX010 into new therapeutic areas (neurological, addiction, trauma).
Revenue / Funding upside	While still early‑stage, each licence can generate supply‑revenue and potentially trigger milestone payments if trials progress. The broadened network also improves the company’s credibility with investors and grant agencies.
Risk mitigation	Demonstrates demand for a standardized psilocybin product, reducing execution risk of Filament’s R&D program.
Overall materiality	Material‑Positive – genuinely new, market‑moving information that strengthens the growth narrative but does not yet constitute a game‑changing catalyst (e.g., FDA approval).

Red Light Holland develops functional mushroom products for consumer markets while building a regulated psychedelic pipeline through its subsidiary Filament Health. The flagship psychedelic asset is PEX010, a naturally‑derived, pharmaceutical‑grade psilocybin truffle extract. PEX010 is already supplied to >70 research sites and holds FDA/Health Canada authorizations for clinical trials.